Published on 9 May 2024 on Benzinga via Yahoo Finance
What's Going On With Dermatitis-Focused RAPT Therapeutics Stock On Thursday?
On Thursday, RAPT Therapeutics Inc. (NASDAQ:RAPT) announced that it has decided to close and unblind both its Phase 2b trial of zelnecirnon (RPT193) in atopic dermatitis (AD) and its Phase 2a trial of zelnecirnon in asthma.
Both clinical trials were placed on clinical hold by the FDA in February 2024 based on a serious adverse event of liver failure requiring a transplant in one patient in the AD trial.